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Abstract 
 
Aims  Mucoepidermoid carcinomas (MEC) are the most common malignant neoplasms of 
salivary glands but are uncommon in other sites. Salivary gland MEC are most frequently 
associated with CRTC1-MAML2 translocations. Exceedingly rare MEC of the breast 
demonstrate a basal-like and often triple (estrogen and progesterone receptor, HER2) negative 
immunophenotype, with a single case previously reported to show MAML2 rearrangement, 
although the fusion partner was not known. Comprehensive genomic studies of breast MEC are 
lacking. In this study, we analyzed the immunophenotype and molecular landscape of two 
breast MEC to elucidate the pathogenesis of these rare tumors.  
Methods and Results  Two breast MEC were subjected to capture-based next-generation DNA 
sequencing of 479 cancer-related genes. The presence of the CRTC1-MAML2 fusion transcript 
was interrogated by reverse-transcriptase polymerase chain reaction. In addition, the 
immunoprofiles of breast MEC were compared to salivary gland MEC. Both breast MEC 
harbored CRTC1-MAML2 fusions. In contrast to most triple-negative breast carcinomas of no 
special type, the mutational burden of MEC was very low, with one case demonstrating only an 
inactivating SETD2 mutation, and the other harboring no somatic variants in genes on the 
panel. No copy number alterations were identified. The immunoprofiles of breast and salivary 
gland MEC were overlapping but not identical.  
Conclusions  The findings highlight MEC as a breast cancer subtype more closely related to its 
salivary gland counterpart than to basal-like/triple-negative breast cancers of no special type. 
 
 
Keywords:  Mucoepidermoid carcinoma; breast cancer; salivary gland; CRTC1-MAML2; cancer 
genetics 
 
Introduction 
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Mucoepidermoid carcinomas (MEC) are the most common malignant neoplasms of the salivary 
gland but also infrequently arise at other sites. It is an exceedingly rare diagnosis in the breast; 
although the estimated incidence is 0.2-0.3% of all mammary tumors, it appears even rarer in 
practice.1, 2 Less than 40 cases of MEC of the breast have been reported in the literature to 
date.2-5 Primary MEC belong to an uncommon group of salivary gland-like neoplasms of the 
breast, which also includes secretory carcinoma, adenoid cystic carcinoma, acinic cell 
carcinoma, and adenomyoepithelioma, among others. Although most lack ER (estrogen 
receptor) and PR (progesterone receptor) expression and HER2 overexpression, prognosis is 
better than expected in comparison to conventional triple-negative breast cancers of no special 
type.4, 6, 7
 
  
MEC have also been reported in the lacrimal gland, esophagus, lung, pleura, thymus, thyroid, 
pancreas, penis, tonsils, and skin.8-17 Morphologic features are similar regardless of site, with 
tumors characterized by variably-sized circumscribed cystic to solid nests and nodules of 
multiple cell populations and prominent extracellular mucin. Intermediate/basaloid, 
epidermoid/squamoid, and mucinous cells are present in varying proportions, although some 
authors differentiate these into four cell types.2, 3, 5, 18 Mucinous or mucin-producing cells are 
usually located at the luminal aspect of the glands and nests and may be tall columnar or 
goblet-shaped with obvious cytoplasmic mucin or be more subtle, requiring special stains to 
highlight the mucin. Intermediate cells are most concentrated at the tumor periphery and are 
small with high nuclear-to-cytoplasmic ratio and oval hyperchromatic nuclei. Epidermoid cells 
are polygonal with well-defined borders and abundant eosinophilic cytoplasm.19 Focal 
intercellular bridges may be observed in rare cases, but squamous pearls or individual cell 
keratinization should be absent. Cytologic features may also include clear cell or oncocytic 
change. A prominent lymphocytic infiltrate is often seen around tumor nodules, which in salivary 
gland is also referred to as tumor-associated lymphoid proliferation (TALP). Reports about in 
situ components vary.5, 20 The most commonly used grading systems for MEC in the salivary 
gland are the Brandwein and Armed Forces Institute of Pathology (AFIP) methods. These three-
tiered and point-based systems incorporate the relative proportion of cystic components and the 
presence of neural invasion, necrosis, mitotic rate, and nuclear anaplasia (as well as vascular 
and bone invasion in Brandwein) to equate to low, intermediate, or high grade.21, 22 In breast 
MEC, the AFIP system and the modified Scarff-Bloom-Richardson (SBR) system appear largely 
interchangeable and yield similar prognostic data.19
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The most common translocation of salivary gland MEC fuses exon 1 of CRTC1 at chromosome 
19p13 to exons 2-5 of MAML2 at chromosome 11q21. Alternative fusions with CRTC3 have 
also been described.23 Low-grade tumors are more likely to be fusion-positive than high-grade 
tumors. The extent to which the presence of the CRTC1-MAML2 translocation influences clinical 
outcome in salivary gland tumors is unclear.24-26 Molecular characterization of breast MEC is 
scant. One case demonstrated an 11q21 deletion at the site of the MAML2 gene, but a fusion 
partner was unknown.5
 
 Given the lack of genomic data or comparative genetic studies, the 
relatedness of MEC of the breast to analog tumors arising in other sites, as well as conventional 
basal/triple-negative breast cancers, remains uncertain. 
In this study, we demonstrate for the first time the presence of the CRTC1-MAML2 fusion 
transcript in MEC of the breast. In addition, we used capture-based next-generation sequencing 
of 479 cancer-related genes to more comprehensively characterize the genomics of two breast 
MEC. The findings shed light on our understanding of breast MEC biology and may help explain 
the favorable clinical behavior of these tumors. 
 
 
Materials and Methods 
 
Case selection 
This study was approved by the institutional review boards of the University of California San 
Francisco (UCSF) and the University of Massachusetts Medical School-Baystate. Two breast 
MEC were confirmed by experienced breast pathologists (Y.C. and C.N.O.) using a combination 
of routine hematoxylin and eosin (H&E)-stained sections, immunohistochemistry, and genetic 
findings. Selected findings in case 2 were previously reported.5
 
 
Tissue microarray construction 
Tissue microarrays (TMA) were created from low-grade MEC of salivary gland origin. Three 2-
mm punch biopsy tissue cores, with each core containing the three cell types of MEC, were 
obtained from each tumor for analysis. Positive and negative on-slide controls consisted of 
normal breast, normal salivary gland, and invasive ductal carcinoma, not otherwise specified. 
 
Immunohistochemistry 
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The following antibodies were used: CK7 (OV-TL12/30, 1:100, DAKO, Santa Clara, CA, USA), 
Cam5.2 (1:100, Becton Dickinson, Franklin Lakes, NJ, USA), CK5/6 (D5/16B4, 1:200 with anti-
background, Millipore, Billerica, MA, USA), MUC4 (8G7, 1:500, Millipore), MUC5AC (MRQ-19, 
undiluted, Cell Marque, Rocklin, CA, USA), GATA3 (L50-823, undiluted, Ventana, Tucson, AZ,  
USA), mammaglobin (304-1A5, 1:4, DAKO), gross cystic disease fluid protein 15 (GCDFP-15; 
23A3, undiluted, Covance, Dedham, MA, USA), p63 (4A4, undiluted, Ventana), SMM (SMMS-1, 
1:300, DAKO), calponin (26A11, undiluted, Leica Biosystems, Buffalo Grove, IL, USA), SMA 
(alpha sm-1, undiluted, Leica Biosystems), ER (SP1, undiluted, Ventana), PR (1E2, undiluted, 
Ventana), HER2 (4B5, undiluted, Ventana), and androgen receptor (AR; SP107, undiluted, Cell 
Marque). Antigen retrieval was as follows: for SMA—none; for CK7, Cam5.2, CK5/6, MUC4, 
mammaglobin, GCDFP-15, p63, and SMM—Bond epitope retrieval solution 1 (Leica 
Biosystems); for calponin—Bond epitope retrieval solution 2 (Leica Biosystems); and for 
GATA3, MUC5AC, ER, PR, HER2, and AR—Cell conditioning solution 1 (Ventana). For ER, 
PR, and HER2, positive staining was defined according to ASCO/CAP guidelines.27, 28
 
 For the 
two breast MEC, immunohistochemistry was performed and evaluated on standard sections, 
whereas TMA was applied for MEC of salivary gland origin. 
MAML2 fluorescence in situ hybridization    
Dual-color fluorescence in situ hybridization (FISH) was performed using 3’ MAML2 DNA 
(clones CTD-2544I7, RP11-936C10, RP11-1123F20, CTD-252L1, and RP11-7D4) labeled with 
SpectrumGreen dUTP (Abbott Molecular/Vysis Products, Abbott Park, IL, USA) and 5’ MAML2 
DNA (clones RP11-8N17, CTD-2325K3, and RP11-1056O10) labeled with SpectrumOrange 
dUTP (Abbott Molecular/Vysis Products). The probe set was applied to 5 micron-thick unstained 
formalin-fixed paraffin-embedded (FFPE) sections on glass slides, hybridized, and washed as 
previously described.26
 
 Enumeration of the fusion and break-apart signals was conducted using 
an Applied Imaging Workstation (Foster City, CA, USA). In each case, 100 cells were analyzed 
in the targeted region. 
Detection of CRTC1-MAML2 fusion by RT-PCR 
Total RNA was extracted from 10 micron-thick unstained FFPE sections using the RNeasy 
FFPE Isolation Kit (Qiagen, Hilden, Germany), followed by reverse-transcription polymerase 
chain reaction (RT-PCR) using SuperScript III One-Step RT-PCR System (ThermoFisher 
Scientific, Foster City, CA, USA) with previously reported primers CRTC1 5′-
TCGCGCTGCACAATCAGAAG-3′ and MAML2 5′-GGTCGCTTGCTGTTGGCAGG-3′.29, 30 
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These products were diluted 1:50 and subjected to a nested PCR with inner primers CRTC1 5’-
GAGGTCATGAAGGACCTGAG-3’ and MAML2 5’-TTGCTGTTGGCAGGAGATAG-3’.29, 30
 
 
Products were resolved by agarose gel electrophoresis and Sanger sequenced using BigDye 
terminator chemistry (ThermoFisher Scientific) following standard techniques. 
Capture-based next generation DNA sequencing 
Capture-based next generation sequencing was performed at the UCSF Clinical Cancer 
Genomics Laboratory, using an assay (UCSF500 panel) that targets the coding regions of 479 
cancer-related genes, select introns from 41 genes (not including CRTC1 or MAML2), and the 
TERT promoter, with a total sequencing footprint of 2.8 Mb (Supplementary Table S1). 
Sequencing libraries were prepared from genomic DNA of tumor and matched normal formalin-
fixed, paraffin-embedded tissue extracted from macrodissected unstained sections. Target 
enrichment was performed by hybrid capture using a custom oligonucleotide library. 
Sequencing was performed on a HiSeq 2500 (Illumina, San Diego, CA, USA). Duplicate 
sequencing reads were removed computationally to allow for accurate allele frequency 
determination and copy number calling. The analysis was based on the human reference 
sequence UCSC build hg19 (NCBI build 37), using the following software packages: BWA: 
0.7.10-r789, Samtools: 1.1 (using htslib 1.1), Picard tools: 1.97 (1504), GATK: 2014.4-3.3.0-0-
ga3711, CNVkit: 0.3.3, Pindel: 0.2.5a7, SATK: 2013.1-10- gd6fa6c3, Annovar: v2015Mar22, 
Freebayes: 0.9.20 and Delly: 0.5.9.31-40
 
 Only insertions/deletions (indels) up to 100 bp in length 
were included in the mutational analysis. Somatic single nucleotide variants and indels were 
visualized and verified using Integrated Genome Viewer. Genome-wide copy number analysis 
based on on-target and off-target reads was performed by CNVkit and Nexus Copy Number 
(Biodiscovery, Hawthorne, CA, USA). 
 
Results 
 
Clinical data 
Case 1 
A 53-year-old woman presented with a circumscribed nodule in the left breast on screening 
mammogram. Diagnostic mammogram revealed a mildly lobulated 1 cm nodule at 12 o’clock, 2 
cm from the nipple. Ultrasound demonstrated a 0.9 cm heterogeneous mass with a mildly 
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nodular contour. Needle core biopsy was performed; the initial diagnosis was reported as 
“carcinoma with mucin secretion and squamoid features.” Fluorescence in situ hybridization was 
subsequently performed and was positive for MAML2 and negative for ETV6 gene 
rearrangements. An addendum diagnosis of “low-grade mucoepidermoid carcinoma” was 
issued. The patient underwent subsequent wire-localized partial mastectomy and sentinel node 
lymphadenectomy; histologic examination confirmed the diagnosis, revealing a 1.6 cm tumor 
with negative margins and lymph nodes. The tumor was low grade by the AFIP grading system 
and grade 1 by the modified SBR system. Biomarker testing was negative for ER, PR, and 
HER2. She was treated with partial breast radiation and alive and well at sixteen months after 
surgery. 
 
Case 2 
The clinical data of case 2 were previously reported.5
 
 Briefly, a 49-year-old woman presented 
with a palpable right breast mass. Mammogram demonstrated a 1.5 cm round mass at 12 
o’clock, as well as a 3 cm area of increased density in the posterior medial right breast. The 
patient underwent modified radical mastectomy with sentinel node lymphadenectomy and 
axillary dissection. Histologic examination demonstrated mucoepidermoid carcinoma of at least 
5 cm with one positive sentinel lymph node. The tumor was intermediate grade by the AFIP 
system and grade 2 by the modified SBR system. Biomarker testing was negative for ER, PR, 
and HER2. She was treated with chemotherapy and alive and well at 1 year after diagnosis. 
Microscopic features of breast mucoepidermoid carcinomas 
H&E sections of both breast MEC showed histologic features characteristic of MEC. Both 
tumors had broad pushing margins associated with a peripheral dense lymphoplasmacytic 
infiltrate (Figure 1A). The neoplastic cells were variably arranged in macrocystic or 
microcystic/cribriform structures and solid nests, with basophilic and/or eosinophilic secretions 
filling the cystic spaces (Figure 1B,C). Intermediate and epidermoid cells were well-represented 
(Figure 1D); mucinous cells were morphologically more subtle but could be highlighted with a 
mucicarmine stain (Figure 1E). In the partial mastectomy specimen of case 1, the central portion 
of the tumor was predominantly composed of large irregular cysts, with smaller irregular nodules 
scattered at the periphery (Figure 1C). Case 2 demonstrated extensive ductal carcinoma in situ 
(DCIS), with expanded lobules and ducts lined by variable numbers of intermediate, epidermoid, 
and mucinous cells and forming fenestrations filled with basophilic secretions (Figure 1F). There 
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were two foci of microinvasion consisting of small irregular nests with a desmoplastic response 
(ref 5, Figure 1). Lymphovascular invasion was not identified in either case.  
 
Immunohistochemical features of breast and salivary gland mucoepidermoid carcinomas 
Both breast MEC expressed low molecular weight cytokeratins (LMWCK: CK7, CAM5.2), high 
molecular weight cytokeratins (HMWCK: CK5/6), and p63, with immunohistochemistry 
differentially highlighting the various cell populations and their distribution. Intermediate cells 
were positive for p63 and HMWCK and negative for LMWCK; epidermoid cells reacted with both 
LMWCK and HMWCK; and mucinous cells preferentially expressed LMWCK (Figure 2A,B). The 
peripheral p63 staining of intermediate cells could be difficult to distinguish from myoepithelial 
cell staining (Figure 2C); however, the invasive tumor was negative for other myoepithelial cell 
markers, including SMM (Figure 2D), calponin, and SMA. The tumor in case 2 consists 
predominantly of DCIS with foci of microinvasion; the DCIS and invasive components show 
similar cytomorphology. This scenario illustrates the limited utility of p63 alone as a 
myoepithelial cell marker in this context. The staining of peripheral myoepithelial cells by p63 
may be difficult to discern from the prominent co-staining of intermediate cells in DCIS, but an 
intact myoepithelial layer can be highlighted by positive SMM (Figure 2E) and calponin staining. 
 
The immunoprofiles of the two breast MEC were compared to seven salivary gland MEC 
analyzed by TMA (Table 1 and Figure 2F-H). Both breast and all seven salivary gland MEC 
were negative for ER, PR, and HER2 by ASCO/CAP guidelines. Breast and salivary gland MEC 
expressed CK5/6 and MUC4 and showed no to minimal expression of GCDFP-15 and AR (0-
5% staining). Both breast MEC showed patchy or diffuse GATA3 and mammaglobin staining, in 
contrast to salivary gland MEC, in which staining for these markers was absent or focal (≤10%) 
in most cases (7/7 and 6/7, respectively). In contrast, 5/7 salivary gland MEC but neither of the 
breast MEC showed patchy MUC5AC expression. Of note, while cytokeratins and p63 
demonstrated differential expression depending on the tumor cell types, other markers did not 
exhibit this staining pattern. 
 
Identification of CRTC1-MAML2 translocation in breast mucoepidermoid carcinomas 
FISH was positive for MAML2 gene rearrangement in both breast MEC (Figure 3A-C). Both 
tumors demonstrated one green/orange fusion signal, reflecting a normal MAML2 locus. Case 1 
additionally revealed one separate green and one separate orange signal (Figure 3B), indicative 
of a translocation event involving one MAML2 gene. In case 2, one green signal was 
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accompanied by loss of the orange signal (Figure 3C), indicating deletion of the 5’ portion of the 
MAML2 locus. RT-PCR analysis revealed CRTC1-MAML2 fusion transcripts in both cases 
(Figure 4A), which were confirmed by Sanger sequencing (Figure 4B). 
 
Next generation DNA sequencing of breast mucoepidermoid carcinomas 
Both breast MEC were subjected to targeted sequencing of 479 cancer-related genes. The 
mean target sequencing coverage was 724 and 507 unique reads per target interval in cases 1 
and 2, respectively. No non-silent single nucleotide variants or indels were detected in case 1. 
Case 2 demonstrated a solitary pathogenic nonsense mutation in SETD2 (p.S543*). No copy 
number alterations were identified in either case. No pathogenic germline variants associated 
with increased cancer risk were identified in either patient. 
 
 
Discussion 
 
In this study, we describe the morphologic features, immunophenotype, and detailed genetic 
landscape of two breast MEC. The characteristic histologic features of MEC are distinctive in 
the breast. However, as pathologists may not be familiar with this rare subtype of breast cancer, 
MEC can be confused with various benign and malignant conditions when assessing limited 
material on core biopsy or fine needle aspiration, depending on the architectural pattern and 
dominant cell type (Table 2). Partially sampled MEC with macrocystic architecture could easily 
be misinterpreted as simple cysts. Microcystic-predominant architecture may raise consideration 
of cribriform pattern DCIS. On the other hand, the heterogeneous cell populations with bland 
cytology and irregular fenestrations can mimic usual ductal hyperplasia, which may be further 
confounded by positive CK5/6 staining. Epidermoid cells and the immunophenotype (positive 
CK5/6 and p63 and triple-negative) may also be confused with squamous metaplasia or a 
squamous metaplastic carcinoma. Lastly, low-grade MEC could be mistaken for secretory 
carcinoma, another rare salivary gland-type carcinoma.41 Both tumors can have a prominent 
cystic component, abundant PAS-D positive secretory material, and cytologically bland cells 
which may have eosinophilic, clear, or vacuolated cytoplasm. In addition, both are 
immunohistochemically positive for mammaglobin, MUC4, and CK5/6 and negative for ER, PR, 
and HER2. However, in contrast to secretory carcinoma, MEC is consistently positive for p63 
and is usually negative or only focally positive for S100. Distinction can be definitively 
established by FISH, using MAML2 and ETV6 break-apart probes, as in case 1. 
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Breast MEC and its salivary gland counterpart share histopathologic features and have an 
overlapping immunophenotype. However, although our study is limited by the small number of 
cases of these rare tumors, we note subtle differences in the morphology and 
immunohistochemical profile of tumors from these two sites. Mucinous cells in the two breast 
MEC lacked tall columnar or goblet cytology, which is often observed in salivary gland MEC and 
has been noted in a previous report.19 Although MEC from both sites demonstrate a basal-like 
immunophenotype (ER, PR, and HER2 negative and CK5/6 positive) and express MUC4, 
breast MEC show strong GATA3 and mammaglobin expression, whereas the salivary gland 
tumors are negative or only minimally positive for these latter markers. In contrast, MUC5AC 
expression, which has been previously reported in salivary gland MEC,42 is absent or scant in 
breast MEC. In this context, it is interesting to note that a prior study of lung MEC found lack of 
expression of the pulmonary markers TTF-1 and napsin A in these tumors,8
 
 suggesting that 
MEC arising in some but not all sites may retain tissue-specific expression patterns, despite 
otherwise similar morphologic and genetic features. Analysis of more cases is necessary to 
confirm these observations. 
Ours is the first study to demonstrate the presence of CRTC1-MAML2 fusion typical of salivary 
gland MEC in breast MEC and to analyze the genomics of these rare tumors using next-
generation sequencing of a large panel of cancer-related genes. Both of our cases harbored 
MAML2 rearrangement by FISH and demonstrated the CRTC1-MAML2 fusion transcript by RT-
PCR. Both tumors showed a simple genome with no copy number alterations and demonstrated 
a very low mutational burden of genes on the panel, with an inactivating SETD2 mutation in one 
case as the only identified somatic nonsynonymous variant. SETD2 is a tumor suppressor gene 
that encodes a histone methyltransferase responsible for trimethylation of lysine 36 of histone 
H3 (H3K36me3). Most prevalent in clear cell renal cell carcinoma, inactivating mutations have 
been described in multiple cancers.43, 44 SETD2 mutations have been rarely reported in breast 
tumors (at most ~3% of cases), notably only in luminal A cancers and phyllodes tumors but not 
in triple-negative breast carcinomas.45-50 No SETD2 alterations have been reported to date in 
MEC of the salivary gland,51
 
 and the significance of this isolated finding in one breast MEC is 
uncertain.  
Comprehensive molecular studies of triple-negative breast carcinomas have shown a 
heterogeneous mutational milieu with frequent TP53 and PIK3CA alterations.45-49, 52-56 However, 
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these studies have generally not included triple-negative salivary gland-like tumors that can 
arise in the breast, including secretory carcinomas, acinic cell carcinomas, and adenoid cystic 
carcinomas, as well as MEC and even rarer types.1, 5, 7, 19, 57-59 Recent studies suggest that 
secretory carcinomas and adenoid cystic carcinomas of the breast are genetically more similar 
to their respective salivary gland counterparts than they are to other triple-negative 
carcinomas.57, 60 In contrast, acinic cell carcinomas arising in the breast harbor frequent TP53 
mutations and complex patterns of copy number alterations, which are not present in salivary 
gland acinic cell carcinomas, suggesting that these two tumors are not related despite their 
histologic similarity.61, 62 The molecular landscape of salivary gland MEC beyond CRTC1-
MAML2 rearrangement have only been explored recently.51, 63 Wang et al utilized a panel of 315 
cancer-related genes to interrogate 48 salivary gland MEC, including seven low-grade tumors. 
Alterations in common oncogenic drivers such as TP53, PIK3CA, CDKN2A/B, BAP1, ERBB2, 
and BRCA1/2 were frequently detected in intermediate- or high-grade MEC, but were absent or 
each present in only single cases of low-grade tumors.63 Kang et al performed whole exome 
sequencing on 18 salivary gland MEC, including nine low-grade tumors. Although TP53 was 
frequently mutated in intermediate- and high-grade MEC, none of the low-grade tumors had 
TP53 mutations, with the only recurrent mutation in these tumors being POU6F2 (in three 
tumors). In addition, most tumors had a low mutational burden with many (6/9) showing no copy 
number alterations.51
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Table 1: Immunophenotypes of breast and salivary gland mucoepidermoid carcinomas. 
 Breast MEC Salivary gland MEC 
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Immunostain* 1 2 1 2 3 4 5 6 7 
GATA3 90 50 <1 5 0 0 1 0 <1 
Mammaglobin 60 40 0 5 <1 10 15 <1 10 
GCDFP15 0 1 0 <1 0 0 <1 0 0 
ER <1 <1 0 0 0 0 0 0 0 
PR 0 0 0 0 0 0 0 0 0 
HER2 0 0 0 0 1 0 0 0 0 
AR 1 2 <1 1 0 0 1 5 <1 
CK5/6 90 90 70 90 40 90 90 50 70 
MUC4 20 80 80 100 60 70 80 90 80 
MUC5AC 0 <1 20 1 70 5 50 50 70 
 
*Values are percentages of positive-staining tumor cells, except for HER2 where values 
represent staining intensity as defined by the ASCO/CAP guidelines. 
 
Table 2: Morphologic mimics of breast mucoepidermoid carcinoma. 
  
Differential diagnosis 
Features that may 
overlap with MEC 
Features helpful in 
differential diagnosis 
Simple cysts 
Macrocystic architecture with one to 
few cell layers; mucoid material 
alone on limited sampling 
Radiologic-pathologic 
correlation against simple cysts 
in MEC; presence of mucinous 
cells in MEC; negative 
SMM/calponin around cysts of 
MEC 
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UDH 
Heterogeneous cell population with 
bland cytology and irregular 
microcystic spaces; strong positive 
CK5/6 
Presence of mucinous and 
epidermoid cells in MEC; ER 
patchy positive in UDH and ER 
negative in MEC 
DCIS, cribriform pattern 
Rounded ductal contours with 
microcystic/cribriform architecture; 
well-defined cellular borders  
Lack of nuclear polarization 
around spaces in MEC; positive 
CK5/6 and negative ER in 
MEC; negative CK5/6 and 
diffuse strong ER in DCIS 
Metaplastic SCC 
Squamoid tumor cells with 
overlapping immunophenotype 
(triple negative, positive CK5/6 and 
p63)  
Circumscribed nodules of MEC 
versus infiltrative growth of 
SCC; multiple cell types in 
MEC; lack of true keratinization 
in MEC 
Secretory carcinoma 
Prominent cystic components; 
PASD-positive secretory material; 
cytologically bland tumor cells with 
overlapping immunophenotype 
(triple negative, positive 
mammaglobin and MUC4) 
Positive p63 in MEC; positive 
S100 in secretory carcinoma; 
positive MAML2 break-apart 
FISH in MEC; positive ETV6 
break-apart FISH in secretory 
carcinoma 
Abbreviations: MEC – mucoepidermoid carcinoma; UDH – usual ductal hyperplasia; DCIS – ductal 
carcinoma in situ; SCC – squamous cell carcinoma; PASD – Periodic acid-Schiff, diastase; FISH – 
fluorescence in situ hybridization 
 
 
 
 
 
 
Figure 1.  Morphologic features of breast mucoepidermoid carcinomas.  
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(A) Low-power view of case 1 demonstrates variably-sized cystic nodules and nests with a 
prominent lymphoid infiltrate at the edge of the tumor. (B) Cystic architecture is prominent in the 
low-grade lesion. (C) Small irregular solid nests are noted focally. (D) Intermediate, epidermoid, 
and mucinous cells are present in variable proportions with basophilic and eosinophilic 
intraluminal secretions. (E) Mucicarmine stain highlights mucinous cells with cytoplasmic mucin 
vacuoles. (F) In situ component shows similar cytomorphology to invasive tumor as well as a 
periductal lymphoid infiltrate.  
 
 
Figure 2. Immunohistochemical profile of mucoepidermoid carcinomas of the breast and 
salivary gland. 
Immunohistochemical stains for cytokeratins differentially highlight the cell types of breast MEC, 
often in a zoning pattern with their spatial distribution. (A) LMWCK such as CAM5.2 
preferentially stains mucinous and epidermoid cells. (B) HMWCK such as CK5/6 highlights 
intermediate and epidermoid cells. (C) p63 also shows a zoning pattern with staining of 
peripherally-situated intermediate cells which can be confused with myoepithelial cell staining. 
(D) Other myoepithelial markers such as SMM are negative. (E) In contrast, in situ carcinoma 
shows peripheral SMM staining, while p63 (inset) highlights both intermediate and myoepithelial 
cell populations. (F-G) Mammary specific markers are positive in breast MEC, compared to 
MEC in the salivary gland (insets). (F) GATA3 shows patchy to diffuse staining in breast MEC, 
but not salivary gland. (G) Mammaglobin staining is also more diffuse in breast MEC than in 
salivary gland. (H) MUC4 demonstrates positive staining in both. 
Figure 3. MAML2 translocation in breast mucoepidermoid carcinomas. 
Fluorescence in situ hybridization with (A) a MAML2 break apart probe demonstrating (B) one 
separate orange and one separate green signal in case 1 and (C) one green signal and loss of 
the orange signal in case 2.  
 
Figure 4. CRTC1-MAML2 fusion transcript in breast mucoepidermoid carcinomas. 
(A) Amplified RT-PCR products resolved by agarose gel electrophoresis, with 100 bp DNA 
ladder (lane 1), breast MEC case 1 (lane 2), breast MEC case 2 (lane 3), salivary gland MEC 
positive control (lane 4), and water negative controls (lanes 5-6). The expected RT-PCR product 
is 95 bp. (B) Direct (Sanger) sequencing of amplified RT-PCR product confirms presence of 
CRTC1-MAML2 fusion.  
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